Jazz Pharmaceuticals

JAZZ · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

JAZZ · Last close · October 26, 2026

$205.70

Jazz Pharmaceuticals' revenue rose 4.9% to $4.3 billion in fiscal 2025. Its operating margin was −10.1%, down from 17.6% a year earlier. Free cash flow was $1.3 billion, down 4.5%. It paid out $125 million in dividends and buybacks, 10% of free cash flow. The diluted share count fell 7.6%.

Jazz Pharmaceuticals plc Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001232524-26-000013 Updated October 16, 2026

Revenue

$4.3B

4.9%

Operating margin

−10.1%

27.7 pts

Net income

−$356M

$560M a year earlier

Free cash flow

$1.3B

4.5%

Return on capital

−4.2%

13.3 pts

Market cap

$14.3B

Oct 26 close

P/E

14.1x

On $14.63 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Jazz's filings tag only its depreciation as its depreciation and amortization total (US$42 million in 2025), leaving out the US$655 million it amortized on acquired products, so depreciation and amortization, EBITDA and the ratios built on it are left blank.

Charts show fiscal years, from the 10-K filings.

Revenue and margins

Revenue

US$ billions, fiscal years

Margins

Percent of revenue

GrossOperatingNetFree cash flow

Net income and earnings per share

From fiscal 2016 to 2024, earnings per share grew 3.8% a year and net income 4.4% a year, as new shares raised the share count by 7% and diluted each share's earnings. Jazz Pharmaceuticals then lost money in fiscal 2025.

Net income

US$ billions, fiscal years; loss years in red.

Diluted earnings per share

US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity

Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.

Return on capitalReturn on equity

Cash flow

Free cash flow

US$ billions. Cash from operations minus capital expenditure; negative years in red.

Payouts and share count

Dividends and buybacks

US$ billions, cash paid in each fiscal year

DividendsShare buybacks

Diluted share count

Weighted-average diluted shares, millions

Valuation

Two ways to value Jazz Pharmaceuticals yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.

Discounted cash flow (DCF)

A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Jazz Pharmaceuticals' 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.

Value per share on three example scenarios, from Jazz Pharmaceuticals' fiscal 2025 free cash flow of $1.3B, net cash of −$4.0B at December 31, 2025 and 61 million diluted shares, from its filings. The scenarios are fitted to Jazz Pharmaceuticals: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 5.3% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 8%: 7% for a stable business (Pharmaceuticals), plus 1 point for unsteady results (a loss in fiscal 2025); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

From the filings

Starting free cash flow, US$ millions

Cash from operations minus capital spending in fiscal 2025.

Net cash, US$ millions

Cash and short-term investments minus debt and finance leases at December 31, 2025. Negative means net debt.

Diluted shares, millions

Weighted-average diluted shares in fiscal 2025.

Your assumptions

Start from

Fitted to Jazz Pharmaceuticals's own revenue growth, as above. Cautious: growth of 2.5% then 2% a year, 2% after year 10, a 9% discount rate. Base: growth of 5.5% then 4% a year, 2.5% after year 10, a 8% discount rate. Optimistic: growth of 8% then 5.5% a year, 3% after year 10, a 7% discount rate.

Free cash flow growth, years 1 to 5 (% a year)

Free cash flow growth, years 6 to 10 (% a year)

Growth after year 10 (% a year)Long-run growth forever after year 10. Usually close to inflation, and always below the discount rate.

Discount rate (% a year)The yearly return an investor wants for the risk. A higher rate gives a lower value.

Value per share on these assumptions

—

Last close, October 26, 2026: $205.70
Value on these assumptions, against the last close: —

Cash flows in years 1 to 10, valued today: —
Everything after year 10, valued today: —
Plus net cash: —
Share of value from after year 10: —

Projected free cash flow

US$ billions. Each column is one year's projected free cash flow, split into what it is worth today and the part removed by discounting.

Value todayRemoved by discounting

How the value changes with two assumptions

Value per share in US$, with the growth rates above. The highlighted cell matches the current assumptions.

How the model works. Free cash flow grows at the first rate for five years and the second rate for five more, and each year is discounted at the discount rate. Everything after year 10 is valued as year-10 cash flow × (1 + growth after year 10) ÷ (discount rate − growth after year 10), discounted back ten years. Net cash is added and the total is divided by diluted shares. The result depends entirely on the assumptions. It is not a forecast, a price target or a recommendation. The last close is the consolidated US closing price, from Databento.

Price-to-earnings (P/E) method

Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.

Value per share on three example scenarios, from Jazz Pharmaceuticals' earnings per share of $14.63 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28×, the middle of Jazz Pharmaceuticals' own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 9%, 8% and 7%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

Earnings per share, US$

Diluted earnings per share over the four quarters to June 30, 2026, from the 10-Qs and 10-K.

P/E multiple

P/E today is the last close divided by the latest earnings per share, the four quarters' where available. Peers: Amneal Pharmaceuticals, Organon.

Earnings growth in the years ahead (% a year) Starts at Jazz Pharmaceuticals' revenue growth over the last 3 years, 5.3% a year, as the base scenario does.

Earnings per share in the years ahead, US$

Year 1Year 2Year 3Year 4Year 5

Type your own estimate for any year; the years after it carry on at the growth rate.

Apply the multiple to earnings

A multiple on a future year's earnings gives the price then, brought back to today at the discount rate below.

Discount rate (% a year) The yearly return an investor wants for the risk, as in the cash flow model.

Value per share today at this multiple

—

Last close, October 26, 2026: $205.70
Value at this multiple, against the last close: —
Jazz Pharmaceuticals' P/E at the last close: 14.1×

Company	Last close	Earnings per share	P/E today
Amneal PharmaceuticalsAMRX	$21.02	$0.49	42.9×
OrganonOGN	$13.74	$0.78	17.6×
Jazz PharmaceuticalsJAZZ	$205.70	$14.63	14.1×

How the P/E method works. Value per share is earnings per share times the multiple. On a future year's earnings, that gives the price in that year, which is brought back to today at the discount rate: price ÷ (1 + discount rate) for each year ahead. It is quick and easy to compare across companies, but it ignores debt and cash, and earnings can swing with one-off gains and charges, so a multiple says most about steady, profitable businesses. Like the cash flow model, the result depends entirely on the assumptions you choose. It is not a forecast, a price target or a recommendation.

Balance sheet

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	591	882	1,506	2,413	1,392
Debt incl. finance leases	6,057	5,730	5,718	6,114	5,362
Net debt (negative means net cash)	5,465	4,848	4,212	3,701	3,970
Net debt to EBITDA	—	—	—	—	—
Debt to equity	1.5x	1.9x	1.5x	1.5x	1.2x
Interest coverage	1.9x	−2.0x	17.6x	2.3x	−1.7x
Current ratio	3.2x	2.8x	2.2x	4.5x	1.9x
Quick ratio	1.9x	2.0x	1.9x	4.0x	1.7x

US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Insider trades

Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Jazz Pharmaceuticals shares on the open market, and 11 insiders sold $68.0 million, $31.4 million of it under trading plans set up in advance.

Date	Insider	Trade	Shares	Price	Value	Filing
Sep 10, 2026	Neena M PatilEVP & Chief Legal Officer	Sold plan	1,200	$240.94	$289,128	Form 4
Sep 8, 2026	Renee D GalaPresident & CEO	Sold plan	2,000	$243.03	$486,060	Form 4
Sep 1, 2026	Bruce C CozaddDirector	Sold plan	6,000	$250.13	$1.5 million	Form 4
Aug 27, 2026	Robert IannoneEVP, Global Head of R&D & CMO	Sold plan	76,921	$249.70	$19.2 million	Form 4
Aug 3, 2026	Bruce C CozaddDirector	Sold plan	6,000	$252.98	$1.5 million	Form 4
Jul 1, 2026	Bruce C CozaddDirector	Sold plan	6,000	$240.47	$1.4 million	Form 4
Jun 15, 2026	Mark Douglas SmithDirector	Sold plan	1,157	$230.55	$266,746	Form 4
Jun 10, 2026	Neena M PatilEVP & Chief Legal Officer	Sold plan	1,200	$231.83	$278,196	Form 4
Jun 1, 2026	Bruce C CozaddDirector	Sold plan	6,000	$235.12	$1.4 million	Form 4
May 28, 2026	Samantha PearceEVP, Chief Commercial Officer	Sold	6,907	$235.41	$1.6 million	Form 4
May 28, 2026	Neena M PatilEVP & Chief Legal Officer	Sold plan	1,192	$236.97	$282,468	Form 4
May 22, 2026	Rick E WinninghamDirector	Sold	2,741	$241.57	$662,143	Form 4

The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Piotroski F-score

The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.

Test	FY23	FY24	FY25
Net income is positive	Pass	Pass	Fail
Cash from operations is positive	Pass	Pass	Pass
Return on assets rose	Pass	Pass	Fail
Cash from operations exceeds net income	Pass	Pass	Pass
Debt fell relative to assets	Fail	Fail	Pass
Current ratio rose	Fail	Pass	Fail
Share count didn't rise	Fail	Pass	Pass
Gross margin rose	—	—	—
Revenue rose relative to assets	Pass	Pass	Fail
F-score	5 of 8	7 of 8	4 of 8
Accruals ratio	−6.1%	−7.1%	−14.5%

The accruals ratio is net income minus cash from operations, over average total assets.

Compare

Put Jazz Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

Company	Year	Revenue growth	Operating margin	Free cash flow margin	Return on capital	Net debt to EBITDA	F-score	Compare
Jazz Pharmaceuticals	FY25	4.9%	−10.1%	30.4%	−4.2%	—	4
Perrigo	FY25	−2.8%	−26.4%	3.4%	−13.2%	—	4	Compare
Elanco	FY25	6.2%	—	6.0%	−0.1%	5.2x	6	Compare
Amneal Pharmaceuticals	FY25	8.1%	13.1%	8.9%	16.1%	3.8x	7	Compare
Organon	FY25	−2.9%	—	8.7%	5.3%	6.3x	5	Compare

Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score above.

10 years of figures

Fiscal year	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Revenue	1,488	1,619	1,891	2,162	2,364	3,094	3,659	3,834	4,069	4,268
Revenue growth	12.3%	8.8%	16.8%	14.3%	9.3%	30.9%	18.3%	4.8%	6.1%	4.9%
Gross profit	—	—	—	—	—	—	—	—	—	—
Research and development	162	198	227	300	335	506	590	850	884	783
Operating income	592	529	615	532	378	170	−66	579	717	−430
Net income	397	488	447	523	239	−330	−224	415	560	−356
Diluted EPS (US$)	6.41	7.96	7.30	9.09	4.22	−5.52	−3.58	6.10	8.65	−5.84
Diluted shares (millions)	62	61	61	58	56	60	62	72	66	61
Cash flow
Cash from operations	592	693	799	776	900	778	1,272	1,092	1,396	1,356
Capital expenditure	10	29	20	40	15	28	29	24	38	59
Free cash flow	583	664	779	736	885	751	1,243	1,068	1,358	1,297
Dividends paid	0	0	0	0	0	0	0	0	0	0
Share buybacks	278	99	524	301	146	0	0	270	311	125
Acquisitions	1,502	0	0	0	0	6,235	0	0	0	0
Stock-based compensation	99	107	102	111	121	189	222	227	248	291
Balance sheet at fiscal year end
Cash and short-term investments	426	—	310	637	1,058	591	882	1,506	2,413	1,392
Debt incl. finance leases	2,030	1,581	1,596	1,607	2,095	6,057	5,730	5,718	6,114	5,362
Total assets	4,800	5,124	5,204	5,539	6,536	12,299	10,835	11,393	12,012	11,659
Total liabilities	2,923	2,411	2,446	2,428	2,876	8,333	7,750	7,656	7,918	7,341
Shareholders' equity	1,877	2,713	2,757	3,111	3,660	3,965	3,086	3,737	4,094	4,319
Margins and ratios
Gross margin	—	—	—	—	—	—	—	—	—	—
Operating margin	39.8%	32.7%	32.5%	24.6%	16.0%	5.5%	−1.8%	15.1%	17.6%	−10.1%
Net margin	26.7%	30.1%	23.6%	24.2%	10.1%	−10.7%	−6.1%	10.8%	13.8%	−8.3%
Free cash flow margin	39.2%	41.0%	41.2%	34.1%	37.4%	24.3%	34.0%	27.9%	33.4%	30.4%
Return on capital	16.7%	—	—	13.1%	7.6%	1.9%	−0.6%	7.3%	9.1%	−4.2%
Return on equity	22.8%	21.2%	16.4%	17.8%	7.0%	−8.7%	−6.4%	12.2%	14.3%	−8.5%
Return on assets	9.8%	9.8%	8.7%	9.7%	4.0%	−3.5%	−1.9%	3.7%	4.8%	−3.0%
Net debt to EBITDA	—	—	—	—	—	—	—	—	—	—

US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)

Source: Jazz Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Jazz Pharmaceuticals.